<DOC>
	<DOCNO>NCT03029585</DOCNO>
	<brief_summary>This study evaluate NanoPac administer intraperitoneally ( IP ) immediately post-second cytoreductive surgery , follow standard care ( SOC ) intravenous ( IV ) chemotherapy , woman platinum-sensitive recurrent ovarian cancer . The study compare four concentration IP NanoPac ( plus IV chemotherapy ) SOC IV chemotherapy alone .</brief_summary>
	<brief_title>Phase II Study Intraperitoneal NanoPac Patients With Platinum-Sensitive Recurrent Stage III Ovarian Cancer</brief_title>
	<detailed_description>The standard care woman experience recurrence platinum-sensitive ovarian cancer cytoreductive surgery follow intravenous ( IV ) chemotherapy platinum agent ( e.g. , carboplatin ) taxane ( e.g. , paclitaxel ) . Research show administration chemotherapy directly peritoneal cavity ( intraperitoneal [ IP ] chemotherapy ) may provide significant survival benefit woman ovarian cancer combine cytoreductive surgery IV chemotherapy . This study include dose-finding phase efficacy phase evaluate IP NanoPac administer immediately post-second cytoreductive surgery woman platinum-sensitive ovarian cancer . In dose-finding phase , subject enrol dose-escalated cohort three subject receive IP NanoPac 100 , 200 , 300 , 400 mg/m2 plus standard care ( SOC ) IV chemotherapy . Subjects follow disease status 12 month . The two best dos dose-finding phase determine . In efficacy phase , subject randomize 1:1:1 one two best dos plus SOC IV chemotherapy SOC alone .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>First recurrence stage III epithelial ovarian cancer stage IV epithelial cancer nonperitoneal cavity disease limit pleural effusion Platinumsensitive cancer ( recurrence &gt; 6 month prior chemotherapy regimen include platinum agent cytoreductive surgery ) Subject appropriate second cytoreductive surgery treatment IV platinum paclitaxel Ascites &lt; 500 mL ; radiologic ultrasound determination ( presurgery ) â‰¥18 year old Signed informed consent Epithelial ovarian cancer outside peritoneal cavity , exception pleural effusion More one prior cytoreductive surgery Anticipated use concomitant chemotherapy ( protocolspecified agent ) , immunotherapy , radiation therapy Treatment prior investigational agent within 30 day plan instillation NanoPac Known sensitivity study medication component chemotherapy regimen History prior malignancy ovarian remission &gt; 5 year , exception basal cell squamous cell carcinoma cervical carcinoma situ biopsy Ileostomy hepatic resection cytoreductive surgery Women childbearing potential practicing adequate form birth control</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>